#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2372	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2476	281.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1564	1564	C	366	C,A	301,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	2372	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2476	281.5	0	HET	.	.	.	A37T	.	37	37	A	417	417	A	290	A,T	199,56	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3987	276.0	0	.	n	.	0	T695C	SNP	695	695	T	1242	1242	C	278	C	230	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3987	276.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1884	1884	A	320	A	271	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3987	276.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2518	2518	C	348	C	279	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3987	276.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3144	3144	T	296	T,C	239,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3674	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3987	276.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2592	2592	A	372	A	317	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	390	folP	852	852	100.0	folP.l6.c4.ctg.1	1962	59.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1202	1204	AGC	102;102;102	A;G;C	87;85;86	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	836	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	64.5	1	SNP	p	S91F	0	.	.	271	273	TCC	916	918	TCC	65;65;64	T;C,T;C	51;55,1;54	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	836	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	64.5	1	SNP	p	D95G	0	.	.	283	285	GAC	928	930	GAC	64;64;64	G;A,G;C	52;51,1;52	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	836	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3870	64.5	1	SNP	p	D95N	0	.	.	283	285	GAC	928	930	GAC	64;64;64	G;A,G;C	52;51,1;52	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	338	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1703	59.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	650	652	ACC	92;92;92	A;C;C	77;74;79	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	338	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1703	59.5	0	.	p	.	0	R44H	NONSYN	130	132	CGC	665	667	CAC	94;95;96	C;A;C	76;78;80	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	338	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1703	59.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	848	850	CAC	85;84;84	C;A;C	74;76;79	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	338	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1703	59.5	1	SNP	p	G45D	0	.	.	133	135	GGC	668	670	GGC	96;95;96	G,C;G;C	80,1;76;77	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	256	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1308	58.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3397	75.4	1	SNP	p	D86N	0	.	.	256	258	GAC	861	863	GAC	115;115;116	G,T;A,T;C	95,1;88,1;96	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3397	75.4	1	SNP	p	S87W	0	.	.	259	261	AGT	864	866	AGT	115;115;115	A;G;T	96;99;100	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3397	75.4	1	SNP	p	S87I	0	.	.	259	261	AGT	864	866	AGT	115;115;115	A;G;T	96;99;100	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3397	75.4	1	SNP	p	S87R	0	.	.	259	261	AGT	864	866	AGT	115;115;115	A;G;T	96;99;100	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3397	75.4	1	SNP	p	S88P	0	.	.	262	264	TCC	867	869	TCC	115;115;115	T;C,T;C	96;96,1;100	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	738	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3094	71.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1838	1840	GGC	109;109;108	G;G;C	100;97;97	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1480	1482	GCA	102;102;101	G;C;A	86;85;85	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1483	1485	ATC	101;100;100	A;T;C,A	87;85;86,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1495	1497	GTG	101;101;100	G;T;G	88;86;83	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1495	1497	GTG	101;101;100	G;T;G	88;86;83	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1999	2001	ACC	66;66;66	A;C;C	59;60;61	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2053	2055	GCG	60;60;60	G;C;G	53;43;46	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2053	2055	GCG	60;60;60	G;C;G	53;43;46	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2176	2178	GGC	75;76;76	G;G;C	64;63;62	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2185	2187	GGC	78;78;78	G,T;G,T;C,A	65,1;63,1;65,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	626	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2856	65.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2203	2205	CCG	84;83;83	C,G;C;G	67,2;70;69	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	828	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3423	72.4	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1814	1816	CTG	83;84;85	C;T;G	73;72;71	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	396	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2165	54.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	713	713	C	56	C,G	47,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	661	663	GGA	103;103;102	G,T;G;A	85,1;89;85	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	G50N	NONSYN	148	150	GGC	667	669	AAC	104;104;104	A,T;A,G;C	89,1;89,1;86	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	F135L	NONSYN	403	405	TTT	922	924	CTT	96;96;98	C;T;T	78;78;74	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	R143G	NONSYN	427	429	AGA	946	948	GGA	96;95;95	G;G;A	79;78;77	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1030	1032	GGT	102;103;103	G;G;T	88;85;86	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1084	1086	AGC	102;102;102	A;G;C	87;89;89	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1150	1150	T	103	T,G	85,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	1	SNP	p	G120K	0	.	.	358	360	GGT	877	879	GGT	99;100;99	G,A;G;T	85,1;83;84	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	1	SNP	p	A121D	0	.	.	361	363	GCC	880	882	GCC	97;97;96	G,C;C;C	80,1;79;83	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	498	porB1b	1035	1035	95.63	porB1b.l15.c4.ctg.1	1921	76.5	1	SNP	p	A121N	0	.	.	361	363	GCC	880	882	GCC	97;97;96	G,C;C;C	80,1;79;83	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1590	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5307	89.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2286	2288	AAT	90;90;90	A;A;T	77;76;75	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	230	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1291	52.9	1	SNP	p	V57M	1	.	.	169	171	ATG	653	655	ATG	99;99;100	A;T;G	80;81;84	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
